Search Results for "Mylan Atovaquone And Proguanil 250mg 100mg Tablet"

21:55 EST 5th February 2016 | BioPortfolio

Matching Channels

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

Perrigo rejects $26 billion hostile Mylan takeover bid

Perrigo has rejected Mylan’s hostile $26 billion bid after a 60% majority of shareholders were unconvinced by the terms by the Friday deadline. As the offer has now lapsed, Mylan is unable to bid ag...

Perrigo shareholders reject Mylan takeover bid

Mylan needed at least 50% of Perrigo's shares tendered to take over the company but received only 40%, Mylan announced. -More- 

ScarAway Buy Builds Perrigo Value, But Not A Wall Against Mylan

Perrigo’s acquisition of the ScarAway brand is not enough to ward off Mylan’s hostile takeover bid but it could be one of several in the near term that would add more value in an attempt to deter ...

Mylan Says It Will Launch $27.14B Bid for Perrigo

Dutch drugmaker Mylan said it will launch a $27.14 billion offer for Irish generic drug and ingredients maker Perrigo next Monday. Perrigo has already turned down several offers from Mylan, so Mylan ...

Matinas BioPharma Presents Preclinical PK and Efficacy Data of Encochleated Atovaquone in Murine Model at IDWeek 2015

- CATQ – Encochleated Atovaquone – Demonstrates Enhanced Efficacy and Tissue Targeting over Current Formulation - BEDMINSTER, N.J., Oct. 10, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdi...

Mylan Allowed to Continue Takeover Bid for Perrigo

A federal district court judge is allowing Mylan to continue its hostile takeover bid for Perrigo. In Perrigo Company PLC v. Mylan NV, Perrigo claimed Mylan made false statements by saying it expect...

Mylan Launching $27 Billion Bid for Perrigo

Dutch drugmaker Mylan says it will launch a $27.14 billion offer for Irish generic drug and ingredients maker Perrigo. Perrigo has already turned down several offers from Mylan, so Mylan says it will ...

Perrigo, Mylan each make false data charges

Mylan says Perrigo CEO Joseph Papa owns Mylan shares worth $220 million.

Matching PubMed Articles

Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management.

Simplification of antiretroviral therapy enhances a patient's adherence but a new formulation could also lead to new adverse events and changes in daily routine. This study compared medication adheren...

Synthesis of a novel superdisintegrant by starch derivatization with polysuccinimide and its application for the development of Ondansetron fast dissolving tablet.

Disintegrants are the key excipients administered in tablet formulations to boost the decomposition of the tablet into smaller pieces in the gastrointestinal environment, thereby increasing the availa...

Tablet Apps and Dexterity: Comparison Between 3 Age Groups and Proof of Concept for Stroke Rehabilitation.

Touch screen tablet technology might be suitable for self-training of impaired dexterity poststroke. We compared performance of app-based hand activities in individuals without a disability from 3-age...

Suppressed Release of Clarithromycin from Tablets by Crystalline Phase Transition of Metastable Polymorph Form I.

The pharmaceutical properties of clarithromycin (CAM) tablets containing the metastable form I of crystalline CAM were investigated. Although the dissolution rate of form I was higher than that of sta...

Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets.

The therapeutic equivalence of generic and brand name antiepileptic drugs has been questioned by neurologists and the epilepsy community. A potential contributor to such concerns is pharmaceutical qua...

Search Whole site using Google

Quick Search
Advertisement Advertisement